ACHI

Midwest Transplant Network Surpasses Expectations to Save and Enhance Lives in 2023

Retrieved on: 
Lundi, février 5, 2024
Partnership, Haematopoietic system, CCRN, DCU, ACHI, ASCP, Hospital, Patient, Transplant, MSN, Overmyer Network, OPO, Urinalysis, Hope, MTN, Eye, RN, Operating, Dentistry

“What we achieved at Midwest Transplant Network in 2023 reflects the commitment of the staff who do the work every day to support organ donation and transplantation.

Key Points: 
  • “What we achieved at Midwest Transplant Network in 2023 reflects the commitment of the staff who do the work every day to support organ donation and transplantation.
  • The work is hard, and happens in countless ways, but we are all dedicated to the mission of enhancing and saving lives through organ, eye and tissue donation” said Jan Finn, RN, MSN, President & CEO, Midwest Transplant Network.
  • The United Network for Organ Sharing reported that across the country, clinical workers performed more than 46,000 lifesaving transplants in 2023.
  • Incorporated in 1973, Midwest Transplant Network facilitates organ, eye and tissue donation in partnership with hospitals and other professional partners to give hope and share life.

CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting

Retrieved on: 
Mardi, octobre 17, 2023
Science, Biotechnology, Research, Surgery, Health, Health Technology, Genetics, Clinical Trials, Standard of care, Abstract, Paris Institute of Statistics, Society, Laboratory for Experimental Medicine and Surgery in Primates, Parameter, University of Utah, NGS, Assistant, HLA, LIMS, Standard, Caregiver, University, Histocompatibility, Laboratory information management system, St Paul's Cathedral, Chimera, Doctor of Philosophy, ACHI, Kidney transplantation, Biomarker, Laboratory, Patient, Management, Dentistry, Transplant, Nephrology, MD, Immunogenetics, Medicine

These peer-reviewed abstracts demonstrate the scientific validation and utility of CareDx products and solutions.

Key Points: 
  • These peer-reviewed abstracts demonstrate the scientific validation and utility of CareDx products and solutions.
  • The hybrid capture approach to matching is unique to CareDx and gives labs flexibility in gene content and increased robustness over other methodologies.
  • Ahmed Mostafa, MD, PhD, Director, Technical Supervisor, and Clinical Consultant, Histocompatibility and Immunogenetics Laboratory, St. Paul's Hospital—Saskatoon.
  • Virtual Crossmatching and Epitope Analysis as Informational Aids in the Transplant Decision Making Process: A Review of VXMatch and VECTR.

SANTECHTURE LAUNCHES DUO OF RCM SOLUTIONS FOR SAUDI MARKET

Retrieved on: 
Jeudi, juin 15, 2023
SBS, Insurance, Clinical coder, CDI, Vision 2030, GCC, ACHI, RCM, KSA, Pain, CM, Patient, ACS, ICD-10-AM, The Clean Tech Revolution, Artificial intelligence, Automation, Medical device, Kingdom

THYNK offers seamless healthcare information system (HIS) integration, covering all RCM touchpoints across the patient journey, It also focuses on the delivery of real-time and proactive denial management functionality.

Key Points: 
  • THYNK offers seamless healthcare information system (HIS) integration, covering all RCM touchpoints across the patient journey, It also focuses on the delivery of real-time and proactive denial management functionality.
  • The KSA debut of these two next-generation solutions builds on the success of ROBIN, the company's groundbreaking medical billing and claims management platform.
  • This is where SANTECHTURE delivers next-generation innovation and stands at the forefront of the RCM tech-revolution with game-changing solutions designed to ensure that denial rates are kept to a minimum while boosting financial performance."
  • "AI based solutions are both inevitable and fundamental if we are to advance RCM functionality and efficiencies.

SANTECHTURE LAUNCHES DUO OF RCM SOLUTIONS FOR SAUDI MARKET

Retrieved on: 
Jeudi, juin 15, 2023
SBS, Insurance, Clinical coder, CDI, Vision 2030, GCC, ACHI, RCM, KSA, Pain, CM, Patient, ACS, ICD-10-AM, The Clean Tech Revolution, Artificial intelligence, Automation, Medical device, Kingdom

THYNK offers seamless healthcare information system (HIS) integration, covering all RCM touchpoints across the patient journey, It also focuses on the delivery of real-time and proactive denial management functionality.

Key Points: 
  • THYNK offers seamless healthcare information system (HIS) integration, covering all RCM touchpoints across the patient journey, It also focuses on the delivery of real-time and proactive denial management functionality.
  • The KSA debut of these two next-generation solutions builds on the success of ROBIN, the company's groundbreaking medical billing and claims management platform.
  • This is where SANTECHTURE delivers next-generation innovation and stands at the forefront of the RCM tech-revolution with game-changing solutions designed to ensure that denial rates are kept to a minimum while boosting financial performance."
  • "AI based solutions are both inevitable and fundamental if we are to advance RCM functionality and efficiencies.

2022 Ordinary Shareholders’ Meeting of Achiko AG: Shareholders adopt all proposals

Retrieved on: 
Dimanche, janvier 22, 2023
ISIN, Advisory board, Proxy, Research, Annual general meeting, Article, Nomination, National Executive Board of the Boy Scouts of America, USD, Medicine, Entrepreneurship, ACHI, COVID-19, Annual report, Marketing, Holding company, Management

2022 Ordinary Shareholders’ Meeting of Achiko AG: Shareholders adopt all proposals

Key Points: 
  • 2022 Ordinary Shareholders’ Meeting of Achiko AG: Shareholders adopt all proposals
    2022 Ordinary Shareholders’ Meeting of Achiko AG: Shareholders adopt all proposals
    Zurich, 20 December 2022: Corporate News – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) held its Annual General Meeting today at 10:00 CET in Zurich.
  • Due to the Covid-19 pandemic, this Annual General Meeting was held without physical presence of the shareholders in accordance with art.
  • The Board of Directors would like to thank all those who exercised their rights as shareholders in this way.
  • The shareholders voted to discharge the members of the Board of Directors and the Executive Board for the financial year 2021.

2022 Ordinary Shareholders’ Meeting of Achiko AG: Shareholders Adopt All Proposals

Retrieved on: 
Mardi, décembre 20, 2022
ISIN, Advisory board, Proxy, Research, Annual general meeting, Article, Nomination, National Executive Board of the Boy Scouts of America, USD, Medicine, Entrepreneurship, ACHI, COVID-19, Annual report, Marketing, Management

ZURICH, Switzerland, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) held its Annual General Meeting today at 10:00 CET in Zurich.

Key Points: 
  • ZURICH, Switzerland, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) held its Annual General Meeting today at 10:00 CET in Zurich.
  • Due to the Covid-19 pandemic, this Annual General Meeting was held without the physical presence of the shareholders in accordance with art.
  • The Board of Directors would like to thank all those who exercised their rights as shareholders in this way.
  • The shareholders voted to discharge the members of the Board of Directors and the Executive Board for the financial year 2021.

Achiko AG Issues a Convocation Notice to its Shareholders for its Annual General Meeting on December 20, 2022

Retrieved on: 
Vendredi, novembre 25, 2022
ACHI, COVID-19, Proxy, Annual, Union, Annual general meeting, ISIN, Letter, CET, CE marking, Holding company

Due to the Covid-19 pandemic, this years Annual General Meeting will be held in accordance with art.

Key Points: 
  • Due to the Covid-19 pandemic, this years Annual General Meeting will be held in accordance with art.
  • Shareholders may exercise their shareholders rights through the independent proxy only, as further set out in the invitation to the Annual General Meeting.
  • Only shareholders that are registered with their personal information in the Companys shareholder ledger may participate in the Annual General Meeting.
  • Only shareholders entered in the shareholder ledger with the right to vote until December 5, 2022 will be entitled to participate in the Annual General Meeting.

Achiko AG Commences Commercial Deliveries in Indonesia

Retrieved on: 
Lundi, novembre 14, 2022
Hospital, Marketing, ISIN, ACHI, CE marking, Nanoparticle, Aptamer, NU, Nahdlatul Ulama, Gold, COVID-19, Union, LR, OTCQB, School, University, Vaccine, DKI

53 LR Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (Achiko, the Company) is proud to announce that following pilot production with manufacturing partner PT Indofarma Tbk, the Company is now commencing commercial deliveries of its Generation 2 AptameX Covid-19 test kit to Nahdlatul Ulama (NU) and other commercial clients, both starting in and around Jakarta.

Key Points: 
  • 53 LR Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (Achiko, the Company) is proud to announce that following pilot production with manufacturing partner PT Indofarma Tbk, the Company is now commencing commercial deliveries of its Generation 2 AptameX Covid-19 test kit to Nahdlatul Ulama (NU) and other commercial clients, both starting in and around Jakarta.
  • Were excited to commence commercial deliveries in Indonesia.
  • Achiko AG (SIX: ACHI.SW, OTCQB: ACHKF, www.achiko.com ) is developing disruptive diagnostic solutions that put people first.
  • Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field.

Achiko AG Production and Company Update

Retrieved on: 
Mercredi, novembre 2, 2022
Marketing, CEO, Nahdlatul Ulama, GLOBE, LR, Tourism, Health, COVID-19, LMIC, Government, ACHI, Education, Company, Union, First generation, Islam, CE marking, ISIN, Second generation, Pharmaceutical industry

53 LR Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (Achiko, the Company) is proud to announce that it has successfully completed a production test with PT Indofarma Tbk as a precursor to mass production of its Generation 2 AptameX Covid-19 test kit.

Key Points: 
  • 53 LR Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (Achiko, the Company) is proud to announce that it has successfully completed a production test with PT Indofarma Tbk as a precursor to mass production of its Generation 2 AptameX Covid-19 test kit.
  • Were excited to pass this milestone, said Mr. Steven Goh, CEO of Achiko AG.
  • The contract is currently behind, however the Company expects to commence delivery as the Company enters the new year.
  • Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com ) is developing disruptive diagnostic solutions that put people first.

CareDx Presents Latest Data on AlloSeq NGS Solutions and Transplant Innovation at the American Society for Histocompatibility and Immunogenetics Annual Meeting

Retrieved on: 
Mardi, octobre 25, 2022
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Surgery, Health, Clinical Trials, Diamond, Caregiver, Doctor of Philosophy, SEC, ABB, Annual report, Society, Patient, Transplant, Nasdaq, Time, Precision medicine, Histocompatibility, The Meeting, NGS, Genetic distance, CEO, 2021 Essex County Council election, Hematopoietic stem cell transplantation, ACHI, Solution, HLA, Pharmaceutical industry, Immunogenetics, Research

CareDx is proud to be a leading sponsor of this years ASHI meeting to help drive continued innovation in transplantation through our laboratory products, said Reg Seeto, CEO and President of CareDx.

Key Points: 
  • CareDx is proud to be a leading sponsor of this years ASHI meeting to help drive continued innovation in transplantation through our laboratory products, said Reg Seeto, CEO and President of CareDx.
  • Moderated by Curtis Lind, Vice President and Head of Research and Development Products at CareDx, the symposium includes the following:
    NGS-HLA for Solid Organ Transplant: The Time is Now.
  • Cathi Murphey Half, Ph.D., HCLD/CC(ABB), A(ACHI), Director, Histocompatibility and Immunogenetics Laboratory Southwest Immunodiagnostics, Inc.
  • Eight scientific abstracts highlight the use of CareDxs flagship AlloSeq Tx171, which offers laboratory professionals a novel method for matching transplant recipients and potential donors.